m-ethenylphenylacetic acid ethyl ester | 272130-45-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: m-ethenylphenylacetic acid ethyl ester
• 英文别名: ethyl (3-vinylphenyl)acetate；Ethyl 2-(3-vinylphenyl)acetate；ethyl 2-(3-ethenylphenyl)acetate
• CAS: 272130-45-7
• 化学式: C₁₂H₁₄O₂
• 分子量: 190.242
• InChiKey: YVGMZICAAYTYTP-UHFFFAOYSA-N

物化性质

• 沸点：
  270.9±9.0 °C(Predicted)
• 密度：
  1.030±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  m-ethenylphenylacetic acid ethyl ester 在 四氧化锇 、 N-甲基吗啉氧化物 、 sodium periodate 、 碳酸氢钠 作用下， 以 四氢呋喃 、 水 、 叔丁醇 为溶剂， 反应 7.75h， 生成 ethyl 2-(3-formylphenyl)acetate
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues

  摘要：

  N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)-ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K-i = 0.06 mu M. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.

  DOI：

  10.1021/jm990448e
• 作为产物：
  描述：

  3-溴苯乙酸 在 四(三苯基膦)钯 、 硫酸 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 132.0h， 生成 m-ethenylphenylacetic acid ethyl ester
  参考文献：
  名称：

  AMP Deaminase Inhibitors. 3. SAR of 3-(Carboxyarylalkyl)coformycin Aglycon Analogues

  摘要：

  N3-Substituted coformycin aglycon analogues with improved AMP deaminase (AMPDA) inhibitory potency are described. Replacement of the 5-carboxypentyl substituent in the lead AMPDA inhibitor 3-(5-carboxypentyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol (2) described in the previous article with various carboxyarylalkyl groups resulted in compounds with 10-100-fold improved AMPDA inhibitory potencies. The optimal N3 substituent had m-carboxyphenyl with a two-carbon alkyl tether. For example, 3-[2-(3-carboxy-5-ethylphenyl)-ethyl]-3,6,7,8-tetrahydroimidazo[4,5-d] [1,3]diazepin-8-ol (43g) inhibited human AMPDA with a K-i = 0.06 mu M. The compounds within the series also exhibited >1000-fold specificity for AMPDA relative to adenosine deaminase.

  DOI：

  10.1021/jm990448e

文献信息

• [EN] NOVEL DIHYDROPYRIMIDIN-2(1H)-ONE COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS DIHYDROPYRIMIDINE-2(1H)-ONES EN TANT QU'INHIBITEURS DE LA S-NITROSOGLUTATHION RÉDUCTASE
  申请人：N30 PHARMACEUTICALS LLC

  公开号：WO2011038204A1

  公开（公告）日：2011-03-31

  The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这些化合物的药物组合物，以及制备和使用这些化合物的方法。
• Gold Complexes with ADAP Ligands: Effect of Bulkiness in Catalytic Carbene Transfer Reactions (ADAP = Alkoxydiaminophosphine)
  作者：Juan Diego Pizarro、Francisco Molina、Manuel R. Fructos、Pedro J. Pérez

  DOI：10.1021/acs.organomet.0c00343

  日期：2020.7.13

  indicates a steric hindrance higher than those of several NHC, PR3, and P(OR3) ligands, in the context of AuCl(L) complexes. These complexes promote the catalytic transfer of a carbene group from ethyl diazoacetate to alkenes and alkanes. In the case of styrene, both the Csp2–H bonds and the C═C bond are functionalized, the relative ratio depending on the catalyst employed and correlating well with the %VBur

  已经通过一锅简单方案合成了组成为AuCl（ADAP）（ADAP =烷氧基二氨基膦）的金（I）配合物家族，其中在与Au（I）源反应之前就地制备了ADAP配体。结构数据表明，这些ADAP配体具有优于膦或亚磷酸酯配体的反式作用。在AuCl（L）络合物的情况下，对掩埋体积（％V Bur）的评估表明，其位阻高于几种NHC，PR 3和P（OR 3）配体。这些络合物促进卡宾基团从重氮乙酸乙酯转移到烯烃和烷烃的催化转移。对于苯乙烯，C sp 2-H键和C═C键已被官能化，相对比例取决于所用催化剂，并且与％V Bur值密切相关。可用数据表明这些化合物显示出非常相似的电子性质，但空间性质不同，该变量可通过简单地替换合成中所用的起始醇来修饰ADAP配体上的烷氧基而容易地控制。
• Inhibitors of adenosine monophosphate deaminase
  申请人：Gensia Sicor Inc.

  公开号：US05731432A1

  公开（公告）日：1998-03-24

  Novel diazepine derivatives which selectively inhibit adenosine monophosphate deaminase and methods of preparing these compounds are provided. These compounds are useful in treating certain conditions in vivo which may be ameliorated by increased local concentrations of adenosine.

  提供了一种选择性抑制腺苷酸单磷酸脱氨酶并制备这些化合物的方法的新型二氮杂环衍生物。这些化合物在治疗某些可以通过增加腺苷局部浓度来改善的体内疾病方面非常有用。
• Novel Dihydropyrimidin-2(1H)-one Compounds as S-Nitrosoglutathione Reductase Inhibitors
  申请人：Sun Xicheng

  公开号：US20120208817A1

  公开（公告）日：2012-08-16

  The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，其可用作S-亚硝基谷胱甘肽还原酶（GSNOR）抑制剂，包括这种化合物的制药组合物，以及制造和使用它们的方法。
• Dihydropyrimidin-2(1H)-one compounds as S-nitrosoglutathione reductase inhibitors
  申请人：N30 Pharmaceuticals, Inc.

  公开号：US09067893B2

  公开（公告）日：2015-06-30

  The present invention is directed to novel dihydropyrimidin-2(1H)-one compounds useful as S-nitrosoglutathione reductase (GSNOR) inhibitors, pharmaceutical compositions comprising such compounds, and methods of making and using the same.

  本发明涉及一种新型二氢嘧啶-2(1H)-酮化合物，可用作S-亚硝基谷胱甘肽还原酶(GSNOR)抑制剂，包括这种化合物的制药组合物以及制备和使用它们的方法。